Boston Scientific (BSX) Change in Receivables (2020 - 2026)

Boston Scientific has disclosed Change in Receivables across 7 years of filings, most recently posting $117.0 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $117.0 million, up 9.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $279.0 million (down 18.9% YoY), and the FY2025 annual result was $269.0 million, down 23.36% from the prior year.
• Change in Receivables came in at $117.0 million for Q1 2026 at Boston Scientific, up from $98.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $117.0 million in Q1 2026 to a low of $3.0 million in Q3 2023.
• The 5-year median for Change in Receivables is $75.0 million (2023), against an average of $70.3 million.
• Across the five-year window, Change in Receivables slumped 78.57% in 2023 and jumped 1000.0% in 2024, its largest moves.
• Boston Scientific's Change in Receivables stood at $44.0 million in 2022, then jumped by 68.18% to $74.0 million in 2023, then increased by 21.62% to $90.0 million in 2024, then climbed by 8.89% to $98.0 million in 2025, then rose by 19.39% to $117.0 million in 2026.
• The last three Change in Receivables figures came in at $117.0 million (Q1 2026), $98.0 million (Q4 2025), and $32.0 million (Q3 2025), per Business Quant data.